Reuters logo
BRIEF-THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01
October 6, 2017 / 12:37 PM / 13 days ago

BRIEF-THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01

Oct 6 (Reuters) - Therapix Biosciences Ltd

* THERAPIX SIGNS FORMULATION DEVELOPMENT AND CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01

* THERAPIX BIOSCIENCES - ‍ENTERED EXCLUSIVE AGREEMENT WITH CATALENT PHARMA SOLUTIONS FOR FORMULATION, DEVELOPMENT AND CLINICAL MANUFACTURING OF THX-TS01​

* THERAPIX BIOSCIENCES - ‍CATALENT TO DEVELOP THX-TS01 IN SOFTGEL FORM IN SUPPORT OF CO‘S CLINICAL DEVELOPMENT PROGRAM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below